Novartis Valuation Multiples

Novartis Overview

About Novartis

Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.

Founded

1996

HQ

Employees

75.3K

Website

novartis.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $55B

EBITDA: $23B

EV

$318B

Valuation Multiples

Multiples.vc

Start free trial

Novartis Financials

Novartis reported last 12-month revenue of $55B and EBITDA of $23B.

In the same LTM period, Novartis generated $45B in gross profit, $23B in EBITDA, and $17B in net income.

Novartis P&L

In the most recent fiscal year, Novartis reported revenue of $57B and EBITDA of $23B.

Novartis expects next 12-month revenue of XXX and NTM EBITDA of XXX

Novartis Stock Performance

Novartis has current market cap of $294B, and enterprise value of $318B.

Novartis' stock price is $154.25.

Novartis Valuation Multiples

Novartis trades at 5.8x EV/Revenue multiple, and 13.9x EV/EBITDA.

Novartis Financial Valuation Multiples

As of April 12, 2026, Novartis has market cap of $294B and EV of $318B.

Equity research analysts estimate Novartis' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Novartis has a P/E ratio of 17.1x.

Novartis Margins & Growth Rates

Novartis' revenue in the last 12 month grew by 5%.

Novartis' revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $0.3M for the same period.

Novartis' rule of 40 is 41% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Novartis' rule of X is 42% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Novartis Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Novartis M&A Activity

Novartis acquired XXX companies to date.

Last acquisition by Novartis was on XXXXXXXX, XXXXX. Novartis acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Novartis Investment Activity

Novartis invested in XXX companies to date.

Novartis made its latest investment on XXXXXXXX, XXXXX. Novartis invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).